Is MNKD or MNPR more undervalued in 2026?

CirclFi compares MannKind Corporation (MNKD) and Monopar Therapeutics Inc. (MNPR) using 13 institutional-grade valuation models. MNKD has a Quality of Company score of 7.0/10 while MNPR scores 4.3/10.

Which is a better buy — MNKD or MNPR?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MNKD and MNPR valuations compare?

MNKD at $3.64 and MNPR at $64.43 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MNKD vs MNPR Valuation Comparison 2026 — Intrinsic Value Analysis

MNKD

Biotechnology

MannKind Corporation

Quality

7.0

out of 10

Value Trap

SAFE

Price

$3.64

Last close

Models

12/13

Active

MNPR

Biotechnology

Monopar Therapeutics Inc.

Quality

4.3

out of 10

Value Trap

SAFE

Price

$64.43

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	MNKD Fair Value	MNKD Upside	MNPR Fair Value	MNPR Upside
Bayesian DCF	Intrinsic	$0.32	-90.6%	$21.57	-66.5%
Earnings Power Value	Intrinsic	$0.26	-92.9%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$1.82	-49.9%	$6.18	-90.4%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MNKD vs MNPR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MNKD vs MNPR — Which Stock Is More Undervalued?

MNKD scores higher with a 7.0/10 quality rating vs MNPR's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing MannKind Corporation (MNKD) and Monopar Therapeutics Inc. (MNPR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MNKD currently trades at $3.64 with a QOC of 7.0/10, while MNPR trades at $64.43 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).